Literature DB >> 33845903

Farnesoid X receptor via Notch1 directs asymmetric cell division of Sox9+ cells to prevent the development of liver cancer in a mouse model.

Chenxia Lu1, Hanwen Lu2, Mi Chen2, Junyi Zhang2, Dan Qin2, Shenghui Liu2, Xiaodong Li3, Lisheng Zhang4.   

Abstract

BACKGROUND: Asymmetrical cell division (ACD) maintains the proper number of stem cells to ensure self-renewal. The rate of symmetric division increases as more cancer stem cells (CSCs) become malignant; however, the signaling pathway network involved in CSC division remains elusive. FXR (Farnesoid X receptor), a ligand-activated transcription factor, has several anti-tumor effects and has been shown to target CSCs. Here, we aimed at evaluating the role of FXR in the regulation of the cell division of CSCs.
METHODS: The FXR target gene and downstream molecular mechanisms were confirmed by qRT-PCR, Western blot, luciferase reporter assay, EMAS, Chip, and IF analyses. Pulse-chase BrdU labeling and paired-cell experiments were used to detect the cell division of liver CSCs. Gain- and loss-of-function experiments in Huh7 cells and mouse models were performed to support findings and elucidate the function and underlying mechanisms of FXR-Notch1 in liver CSC division.
RESULTS: We demonstrated that activation of Notch1 was significantly elevated in the livers of hepatocellular carcinoma (HCC) in Farnesoid X receptor-knockout (FXR-KO) mice and that FXR expression negatively correlated with Notch1 level during chronic liver injury. Activation of FXR induced the asymmetric divisions of Sox9+ liver CSCs and ameliorated liver injury. Mechanistically, FXR directs Sox9+ liver CSCs from symmetry to asymmetry via inhibition of Notch1 expression and activity. Deletion of FXR signaling or over-expression of Notch1 greatly increased Notch1 expression and activity along with ACD reduction. FXR inhibited Notch1 expression by directly binding to its promoter FXRE. FXR also positively regulated Numb expression, contributing to a feedback circuit, which decreased Notch1 activity and directed ACD.
CONCLUSION: Our findings suggest that FXR represses Notch1 expression and directs ACD of Sox9+ cells to prevent the development of liver cancer.

Entities:  

Keywords:  FXR; Liver cancer stem cell; Notch1; Sox9; Symmetric cell division

Year:  2021        PMID: 33845903     DOI: 10.1186/s13287-021-02298-6

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   6.832


  46 in total

1.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.

Authors:  Terence Kin Wah Lee; Antonia Castilho; Vincent Chi Ho Cheung; Kwan Ho Tang; Stephanie Ma; Irene Oi Lin Ng
Journal:  Cell Stem Cell       Date:  2011-07-08       Impact factor: 24.633

Review 2.  Cancer stem cells: current status and evolving complexities.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

Review 3.  Functional genomic studies: insights into the pathogenesis of liver cancer.

Authors:  Ze-Guang Han
Journal:  Annu Rev Genomics Hum Genet       Date:  2012-06-11       Impact factor: 8.929

Review 4.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

Authors:  Hariharan Easwaran; Hsing-Chen Tsai; Stephen B Baylin
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

5.  Asymmetry-defective oligodendrocyte progenitors are glioma precursors.

Authors:  Sista Sugiarto; Anders I Persson; Elena Gonzalez Munoz; Markus Waldhuber; Chrystelle Lamagna; Noemi Andor; Patrizia Hanecker; Jennifer Ayers-Ringler; Joanna Phillips; Jason Siu; Daniel A Lim; Scott Vandenberg; William Stallcup; Mitchel S Berger; Gabriele Bergers; William A Weiss; Claudia Petritsch
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

6.  WNT/β-Catenin Directs Self-Renewal Symmetric Cell Division of hTERThigh Prostate Cancer Stem Cells.

Authors:  Kai Zhang; Yanjing Guo; Xue Wang; Huifang Zhao; Zhongzhong Ji; Chaping Cheng; Li Li; Yuxiang Fang; Dawei Xu; Helen He Zhu; Wei-Qiang Gao
Journal:  Cancer Res       Date:  2017-02-16       Impact factor: 12.701

7.  CD13 is a therapeutic target in human liver cancer stem cells.

Authors:  Naotsugu Haraguchi; Hideshi Ishii; Koshi Mimori; Fumiaki Tanaka; Masahisa Ohkuma; Ho Min Kim; Hirofumi Akita; Daisuke Takiuchi; Hisanori Hatano; Hiroaki Nagano; Graham F Barnard; Yuichiro Doki; Masaki Mori
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

Review 8.  Cells of origin in cancer.

Authors:  Jane E Visvader
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

9.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

10.  SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma.

Authors:  Takayuki Kawai; Kentaro Yasuchika; Takamichi Ishii; Yuya Miyauchi; Hidenobu Kojima; Ryoya Yamaoka; Hokahiro Katayama; Elena Yukie Yoshitoshi; Satoshi Ogiso; Sadahiko Kita; Katsutaro Yasuda; Ken Fukumitsu; Junji Komori; Etsuro Hatano; Yoshiya Kawaguchi; Shinji Uemoto
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more
  3 in total

1.  Pleiotropic roles of FXR in liver and colorectal cancers.

Authors:  Xiongfei Huang; Mingjie Fan; Wendong Huang
Journal:  Mol Cell Endocrinol       Date:  2022-01-04       Impact factor: 4.102

2.  Inhibition of RFX6 Suppresses the Invasive Ability of Tumor Cells Through the Notch Pathway and Affects Tumor Immunity in Hepatocellular Carcinoma.

Authors:  Mu Song; Mulati Kuerban; Lu Zhao; Xiaolin Peng; Youqin Xu
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

3.  Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.

Authors:  Shiyu Huang; Yanguang Hou; Min Hu; Juncheng Hu; Xiuheng Liu
Journal:  BMC Cancer       Date:  2022-09-19       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.